Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Unravelling the role of denosumab in prostate cancer.

Aragon-Ching JB.

Lancet. 2011 Mar 5;377(9768):785-6. doi: 10.1016/S0140-6736(11)60100-1. Epub 2011 Feb 25. No abstract available.

PMID:
21353698
[PubMed - indexed for MEDLINE]
2.

Breast cancer bone metastases: denosumab or zoledronic acid?

van der Pluijm G.

Nat Rev Endocrinol. 2011 Mar;7(3):134-5. doi: 10.1038/nrendo.2011.18. No abstract available.

PMID:
21343953
[PubMed - indexed for MEDLINE]
3.

Denosumab an option for patients with bone metastasis from breast cancer.

Barton MK.

CA Cancer J Clin. 2011 May-Jun;61(3):135-6. doi: 10.3322/caac.20116. Epub 2011 May 1. No abstract available.

PMID:
21532096
[PubMed - indexed for MEDLINE]
Free Article
4.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.

Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

PMID:
21353695
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

PMID:
21343556
[PubMed - indexed for MEDLINE]
6.

Denosumab: benefits of RANK ligand inhibition in cancer patients.

Lipton A, Jacobs I.

Curr Opin Support Palliat Care. 2011 Sep;5(3):258-64. doi: 10.1097/SPC.0b013e328349731c. Review. Erratum in: Curr Opin Support Palliat Care. 2011 Dec;5(4):369.

PMID:
21826000
[PubMed - indexed for MEDLINE]
7.

Preventing metastases to bone: denosumab or bisphosphonates?

Nanes MS.

J Bone Miner Res. 2010 Mar;25(3):437-9. doi: 10.1002/jbmr.71. No abstract available.

PMID:
20200989
[PubMed - indexed for MEDLINE]
8.

Bone targeted therapy in breast cancer: present and future.

Huober J, Thürlimann B.

Crit Rev Oncol Hematol. 2010 Apr;74 Suppl 1:S7-10. doi: 10.1016/S1040-8428(10)70004-4. Review. No abstract available.

PMID:
20427030
[PubMed - indexed for MEDLINE]
9.

Skeletal-related events in prostate cancer.

Smith MR.

Clin Adv Hematol Oncol. 2012 Aug;10(8):535-6. No abstract available.

PMID:
23073052
[PubMed - indexed for MEDLINE]
10.

Denosumab for bone metastases from breast cancer: a new therapy option?

Aapro MS.

J Clin Oncol. 2011 May 10;29(14):e419-20; author reply e421-4. doi: 10.1200/JCO.2010.33.9150. Epub 2011 Apr 4. No abstract available.

PMID:
21464408
[PubMed - indexed for MEDLINE]
11.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

PMID:
21060033
[PubMed - indexed for MEDLINE]
12.

New developments for treatment and prevention of bone metastases.

Body JJ.

Curr Opin Oncol. 2011 Jul;23(4):338-42. doi: 10.1097/CCO.0b013e328347918b. Review.

PMID:
21519257
[PubMed - indexed for MEDLINE]
13.

Denosumab: second chapter in controlling bone metastases or a new book?

Fornier MN.

J Clin Oncol. 2010 Dec 10;28(35):5127-31. doi: 10.1200/JCO.2010.31.0128. Epub 2010 Nov 8. No abstract available.

PMID:
21060038
[PubMed - indexed for MEDLINE]
14.

A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.

Vignot S, Khayat D.

J Clin Oncol. 2009 Apr 1;27(10):1534-6. doi: 10.1200/JCO.2008.20.7001. Epub 2009 Feb 23. No abstract available.

PMID:
19237628
[PubMed - indexed for MEDLINE]
15.

Treatment and prevention of bone complications from prostate cancer.

Lee RJ, Saylor PJ, Smith MR.

Bone. 2011 Jan;48(1):88-95. doi: 10.1016/j.bone.2010.05.038. Epub 2010 May 31. Review.

PMID:
20621630
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value.

West H.

J Clin Oncol. 2011 Mar 20;29(9):1095-8. doi: 10.1200/JCO.2010.33.5596. Epub 2011 Feb 22. No abstract available.

PMID:
21343550
[PubMed - indexed for MEDLINE]
17.

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S.

J Clin Oncol. 2009 Apr 1;27(10):1564-71. doi: 10.1200/JCO.2008.19.2146. Epub 2009 Feb 23.

PMID:
19237632
[PubMed - indexed for MEDLINE]
18.

Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.

Sorscher SM, Lockhart AC.

J Clin Oncol. 2011 Jul 1;29(19):2735-6; author reply 2736-8. doi: 10.1200/JCO.2011.35.8333. Epub 2011 Jun 6. No abstract available.

PMID:
21646612
[PubMed - indexed for MEDLINE]
19.

Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.

Saad F, Lipton A.

Curr Opin Support Palliat Care. 2010 Sep;4(3):127-34. doi: 10.1097/SPC.0b013e32833ac6d6. Review.

PMID:
20489645
[PubMed - indexed for MEDLINE]
20.

Management of bone metastases in refractory prostate cancer--role of denosumab.

Paller CJ, Carducci MA, Philips GK.

Clin Interv Aging. 2012;7:363-72. doi: 10.2147/CIA.S27930. Epub 2012 Sep 17. Review.

PMID:
23049248
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk